News | August 05, 2024
Divis Laboratories reports Q1 FY25 consolidated PAT at Rs. 430 Cr
Divis Laboratories has reported total income of Rs. 2,197 crores during the period ended June 30, 2024
Divis Laboratories has reported total income of Rs. 2,197 crores during the period ended June 30, 2024
Zydus receives final approval from USFDA for its NDA Zituvimeta, extended-release tablets
The proposed facility is expected to be operational around January, 2027
Divi's Laboratories Limited has reported total income of Rs. 1995 crores during the period ended September 30, 2023
The delegation's visit covered a wide range of topics
Divi's Laboratories Limited has reported consolidated financial results for the period ended September 30, 2021.
Subscribe To Our Newsletter & Stay Updated
